Trending NewsTrending NewsNASDAQ:AARD Aardvark Therapeutics (AARD) Stock Price, News & Analysis $5.38 -0.15 (-2.71%) Closing price 09/18/2026 04:00 PM EasternExtended Trading$5.38 +0.00 (+0.09%) As of 09/18/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsInsider TradesNews and TrendsOwnershipSEC FilingsShort Interest About Aardvark Therapeutics Stock (NASDAQ:AARD) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Aardvark Therapeutics alerts:Sign Up Key Stats Today's Range$5.19▼$5.5950-Day Range$4.92▼$7.9052-Week Range$3.35▼$17.94Volume129,809 shsAverage Volume132,612 shsMarket Capitalization$117.71 millionP/E RatioN/ADividend YieldN/APrice Target$15.33Consensus RatingHold Company Overview Aardvark Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing oral therapies for obesity, hyperphagia and related metabolic disorders. The company’s approach is based on activating bitter taste receptors, which it believes may influence appetite regulation and metabolic signaling without relying on injectable therapies. Aardvark’s lead investigational product, ARD-101, is an oral small-molecule bitter taste receptor agonist being studied for conditions involving excessive hunger and food intake, including hyperphagia associated with Prader-Willi syndrome. The company is also advancing additional programs aimed at obesity and other appetite-related disorders. Based in San Diego, California, Aardvark Therapeutics is focused on research and clinical development and does not yet have an approved commercial product. Its programs are investigational, and their safety and effectiveness remain subject to evaluation in clinical trials.AI Generated. May Contain Errors. Read More Aardvark Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks65th Percentile Overall ScoreAARD MarketRank™: Aardvark Therapeutics scored higher than 65% of companies evaluated by MarketBeat, and ranked 220th out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingHold Consensus RatingAardvark Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.42, and is based on 1 strong buy rating, 5 buy ratings, 4 hold ratings, and 2 sell ratings.Upside PotentialAardvark Therapeutics has a consensus price target of $15.33, representing about 185.0% upside from its current price of $5.38.Amount of Analyst CoverageAardvark Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Aardvark Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Aardvark Therapeutics are expected to grow in the coming year, from ($3.17) to ($2.52) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Aardvark Therapeutics is -1.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Aardvark Therapeutics is -1.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAardvark Therapeutics has a P/B Ratio of 1.10. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.83% of the float of Aardvark Therapeutics has been sold short.Short Interest Ratio / Days to CoverAardvark Therapeutics has a short interest ratio ("days to cover") of 3.77, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Aardvark Therapeutics has recently decreased by 16.65%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAardvark Therapeutics does not currently pay a dividend.Dividend GrowthAardvark Therapeutics does not have a long track record of dividend growth. News and Social Media1.9 / 5News Sentiment-0.01 News SentimentAardvark Therapeutics has a news sentiment score of -0.01. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.56 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 23 news articles for Aardvark Therapeutics this week, compared to 6 articles on an average week.Search InterestOnly 1 people have searched for AARD on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows1 people have added Aardvark Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership1.4 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Aardvark Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $394,930.00 in company stock.Percentage Held by Insiders17.80% of the stock of Aardvark Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsAardvark Therapeutics has minimal institutional ownership at this time.Read more about Aardvark Therapeutics' insider trading history. Receive AARD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aardvark Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. AARD Stock News HeadlinesAARD IMPORTANT DEADLINE: ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Aardvark Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – AARDSeptember 18 at 9:39 PM | globenewswire.comBronstein, Gewirtz & Grossman LLC Urges Aardvark Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor HarmSeptember 18 at 11:24 AM | globenewswire.comA “bloodbath” Is ComingReports suggest some Silicon Valley billionaires are stockpiling gold, guns, and gas masks - or leaving the country entirely - as concerns grow about the next phase of the AI market. One AI insider says investors should reassess their positions before September 30, pointing to a critical shift ahead for tech and AI-related stocks.September 20 at 1:00 AM | TradeSmith (Ad)Lowey Dannenberg, P.C. is Investigating Aardvark Therapeutics, Inc. (NASDAQ: AARD) for Potential Violations of the Federal Securities LawsSeptember 18 at 10:55 AM | globenewswire.comAARD Investors Have Opportunity to Lead Aardvark Therapeutics, Inc. Securities Fraud Lawsuit with SBS LawSeptember 18 at 9:32 AM | globenewswire.comAARD Deadline Alert: SueWallSt Reminds Aardvark Therapeutics, Inc. (AARD) Investors of Securities Class Action Deadline on October 13, 2026September 17 at 10:09 AM | prnewswire.comPomerantz Law Firm Announces the Filing of a Class Action Against Aardvark Therapeutics, Inc. and Certain Officers and Directors - AARDSeptember 17 at 10:00 AM | prnewswire.comNelson Sun Sells 14,754 Shares of Aardvark Therapeutics (NASDAQ:AARD) StockSeptember 12, 2026 | insidertrades.comSee More Headlines AARD Stock Analysis - Frequently Asked Questions How have AARD shares performed this year? Aardvark Therapeutics' stock was trading at $13.13 at the start of the year. Since then, AARD shares have decreased by 59.0% and is now trading at $5.38. How were Aardvark Therapeutics' earnings last quarter? Aardvark Therapeutics, Inc. (NASDAQ:AARD) announced its quarterly earnings results on Tuesday, August, 11th. The company reported ($0.66) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.87) by $0.21. When did Aardvark Therapeutics IPO? Aardvark Therapeutics (AARD) raised $100 million in an IPO on Friday, February 14th 2025. The company issued 5,900,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, BofA Securities, Cantor and RBC Capital Markets served as the underwriters for the IPO. Who are Aardvark Therapeutics' major shareholders? Aardvark Therapeutics' top institutional shareholders include BlackRock Inc. (0.85%), J. Goldman & Co LP (0.19%), Ieq Capital LLC (0.18%) and Susquehanna International Group LLP (0.11%). Insiders that own company stock include Tien-Li Lee and Nelson Sun. View institutional ownership trends. How do I buy shares of Aardvark Therapeutics? Shares of AARD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings8/11/2026Today9/20/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (4m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 AARD's financial health is in the Green zone, according to TradeSmith. AARD has been in this zone for over 4 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:AARD Previous SymbolNASDAQ:AARD CIK1774857 Webaardvarktherapeutics.com Phone(858) 225-7696FaxN/AEmployees28Year Founded2017Price Target and Rating Average Price Target for Aardvark Therapeutics$15.33 High Price Target$47.00 Low Price Target$3.00 Potential Upside/Downside+185.0%Consensus RatingHold Rating Score (0-4)2.42 Research Coverage12 Analysts Profitability EPS (Trailing Twelve Months)($3.21) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$57.59 million Net MarginsN/A Pretax MarginN/A Return on Equity-71.54% Return on Assets-64.94% Debt Debt-to-Equity RatioN/A Current Ratio12.63 Quick Ratio12.63 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.90 per share Price / Book1.10Miscellaneous Outstanding Shares21,880,000Free Float17,989,000Market Cap$117.71 million OptionableN/A Beta3.74 Social Links 7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free Report This page (NASDAQ:AARD) was last updated on 9/20/2026 by MarketBeat.com Staff. From Our Partners$40,000,000,000,000The national debt just hit 40 trillion dollars, and the U.S. now spends more on interest payments than on its ...American Alternative | SponsoredTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...Behind the Markets | SponsoredA “bloodbath” Is ComingReports suggest some Silicon Valley billionaires are stockpiling gold, guns, and gas masks - or leaving the co...TradeSmith | SponsoredBefore Anthropic becomes impossible to ignore...Riot Platforms just struck a 20-year, 191-megawatt data-center agreement tied to Anthropic, reportedly worth 9...The Oxford Club | SponsoredThe Last Gold Bull Market?Former CIA and Pentagon official Jim Rickards says the current gold bull market could be its last. Investment ...Paradigm Press | SponsoredElon Musk to Trigger Next AI Wave on November 11th?Jeff Brown picked Nvidia in 2016, before shares surged 37,800 percent. Now he's identified another AI company ...Brownstone Research | SponsoredNo Wallstreet. No Advisor. No Problem.Savings accounts pay just 0.58 percent interest. Andy Howard, co-founder of Meridian Capital, says liquidity p...Awesomely | SponsoredThe end of AI data centers coming?Marc Chaikin's Power Gauge system flagged Micron before it soared 970 percent, Celestica before a 6,600 percen...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aardvark Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aardvark Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
